Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Acquired in-process research and development expenses by Year
Acquired in-process research and development (AIPR&D) expenses ($M) ($M)
Vertex Pharmaceuticals Acquired in-process research and development expenses: $133M in FY2025, down 97.1% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Collaborative Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquired in-process research and development (AIPR&D) expenses ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 133 | -97.1% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 4,628 | +778.1% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 527 | +356.4% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 116 | -89.5% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Dec 31, 2021 | 1,100 | – | Form 10-K (filed 2024-02-15) ↗ |
Breakdown
What makes up acquired in-process research and development expenses
Cite this data
StockData. (2026). Vertex Pharmaceuticals Acquired in-process research and development expenses ($M), annual FY2021–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/aiprd-exp
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.